Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1996 1
2001 1
2008 1
2009 1
2015 1
2017 1
2018 2
2019 1
2020 1
2021 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Sulfonamido-aryl ethers as bradykinin B1 receptor antagonists.
Cole AG, Metzger A, Brescia MR, Qin LY, Appell KC, Brain CT, Hallett A, Ganju P, Denholm AA, Wareing JR, Ritchie TJ, Drake GM, Bevan SJ, MacGloinn A, McBryde A, Patel V, Oakley PJ, Nunez X, Gstach H, Schneider P, Baldwin JJ, Dolle RE, McDonald E, Henderson I. Cole AG, et al. Among authors: nunez x. Bioorg Med Chem Lett. 2009 Jan 1;19(1):119-22. doi: 10.1016/j.bmcl.2008.11.005. Epub 2008 Nov 6. Bioorg Med Chem Lett. 2009. PMID: 19014884
Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.
Villoslada P, Rovira A, Montalban X, Arroyo R, Paul F, Meca-Lallana V, Ramo C, Fernandez O, Saiz A, Garcia-Merino A, Ramió-Torrentà L, Casanova B, Oreja-Guevara C, Muñoz D, Martinez-Rodriguez JE, Lensch E, Prieto JM, Meuth SG, Nuñez X, Campás C, Pugliese M; NeuroAdvan study. Villoslada P, et al. Among authors: nunez x. Neurol Neuroimmunol Neuroinflamm. 2015 Sep 10;2(5):e147. doi: 10.1212/NXI.0000000000000147. eCollection 2015 Oct. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26405686 Free PMC article.
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators. Vogelmeier CF, et al. Among authors: nunez x. Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x. Respir Res. 2017. PMID: 28720132 Free PMC article. Clinical Trial.
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A. Greulich T, et al. Among authors: nunez x. Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29713156 Free PMC article. Clinical Trial.